MedTrace Logo

Dose-dependent Effect of Rosuvastatin on Long-term Clinical Outcomes After PCI

NCT02859480 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 300

Last updated 2016-08-09

No results posted yet for this study

Summary

This study is a prospective, randomized, open-label, single-center trial designed to compare the 30 month-safety and efficacy between low-dose (5mg/dL) and high-dose (20mg/dL) rosuvastatin treatment for patients with coronary artery disease after percutaneous coronary intervention with the newer drug-eluting stent.

Conditions

Interventions

DRUG

Rosuvastatin 5mg

Rosuvastatin 5mg tablet, q.d., for 30 months

DRUG

Rosuvastatin 20mg

Rosuvastatin 5mg tablet, q.d., for 30 months

Sponsors & Collaborators

  • Samjin Pharmaceutical Co., Ltd.

    collaborator INDUSTRY

  • Korea University Anam Hospital

    lead OTHER

Principal Investigators

  • Hyung Joon Joo, MD, PhD · Department of Cardiology, Korea University Anam Hospital

  • Do-sun Lim, MD, PhD · Department of Cardiology, Korea University Anam Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
35 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-09-30
Primary Completion
2019-06-30
Completion
2019-12-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02859480 on ClinicalTrials.gov